Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, T-Cell 4Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Recurrence 2Lymphoma, T-Cell, Peripheral 2Leukemia 2Squamous Cell Carcinoma of Head and Neck 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Follicular 1Immunoblastic Lymphadenopathy 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Enteropathy-Associated T-Cell Lymphoma 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 20fludarabine phosphate 16Peripheral Blood Stem Cell Transplantation 11Tacrolimus 10Mycophenolic Acid 10Whole-Body Irradiation 9Cyclosporine 8Methotrexate 7Etoposide 7Busulfan 7Antilymphocyte Serum 7Vincristine 6Prednisone 6Melphalan 6Doxorubicin 5Rituximab 4Transplantation 3Sirolimus 3Radiotherapy 3Methylprednisolone 3Gemcitabine 3Brentuximab Vedotin 3Alemtuzumab 3nelarabine 2merphos 2etoposide phosphate 2Therapeutics 2Prednisolone 2Panobinostat 2Lenalidomide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Immunoblastic Lymphadenopathy × duvelisib × Clear all
NCT04803201 2026-06-02

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

Alliance for Clinical Trials in Oncology

Phase 2 Suspended
170 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡